J

Johnson & Johnson

Makes prescription drugs and medical devices

Finance Compliance Manager - Technology and Data

Full-TimeUpdated on 10/24/2026
No salary listed
Senior, Expert
Bachelor's
Bengaluru, Karnataka, India
Hybrid
Risk & ComplianceInternal Audit & Controls

About the job

Requirements
  • A bachelor's degree in Finance or Economics, or a related field, is required.
  • At least 8 years of experience in Finance roles is required; experience in significant system transformation projects is preferred.
  • A solid grasp of financial and IT internal controls is required.
  • A solid grasp of SOX 404, US GAAP, and IFRS is required.
  • A solid grasp of the supply chain environment is required.
  • The ability to proactively identify and mitigate process risks is required.
  • An understanding of continuous process improvement techniques is required.
  • The ability to anticipate needs, assess and manage business risks, escalate issues that may impact processes globally, and manage through crises and ambiguity is required.
  • Experience working in a sophisticated, multi-ERP or system environment is required.
  • People leadership skills and the ability to collaborate in a highly matrixed environment are required.
Responsibilities
  • Support the application of Finance Transformation Compliance governance to SAP-driven transformation initiatives, focusing on technology, system configuration, and data-related risks.
  • Translate enterprise ICFR, SOX, and IT General Controls frameworks into transformation-specific compliance requirements for SAP S/4HANA and related technologies.
  • Act as the primary compliance point of contact for SAP and technology-related compliance topics within assigned transformation programs and value streams.
  • Guide and lead technology-focused risk assessments, including SAP application risks, IT General Controls, and data integrity considerations.
  • Ensure consistent design and application of IT General Controls, including access management, organizational change, computer operations, and configuration controls.
  • Provide compliance guidance on SAP configurations, workflows, and system-enabled controls to ensure alignment with internal control and SOX requirements.
  • Define and apply compliance expectations for system interfaces, including source-to-target controls, error handling, reconciliation, and supervisory mechanisms.
  • Review and challenge program-level compliance artifacts related to SAP and IT controls, ensuring completeness, consistency, and alignment with approved methodologies.
  • Supervise technology- and data-related compliance risks across transformation initiatives, identify emerging issues, and escalate material risks to the Senior Manager.
  • Coordinate across programs to manage shared SAP platforms, common interfaces, and cross-system dependencies from a compliance perspective.
  • Contribute to the development and refinement of compliance guidance and methodologies related to IT General Controls, SAP risks, and data integrity.
  • Ensure documentation and traceability of compliance decisions, assessments, and governance outcomes within assigned transformation initiatives.
  • Promote a risk-based, pragmatic approach to technology and data compliance that enables Finance Transformation objectives while maintaining control effectiveness.
  • Serve as a domain expert for auditors, supporting discussions about IT General Controls, SAP-related risks, and technology control frameworks by explaining design principles, risk assessments, and ITGC risks and control matrices.
Desired Qualifications
  • Experience in significant system transformation projects.
  • Experience with SAP S/4HANA.
  • Agility Jumps.
  • Business Continuity Management (BCM).
  • Compliance frameworks.
  • Compliance management.
  • Financial analysis.
  • Financial risk management (FRM).
  • Internal controls.
  • Mentorship.
  • Process improvements.
  • Regulatory environment.
  • Risk assessments.
  • Risk measurement.
  • Stakeholder engagement.
  • Systems thinking.
  • Tactical planning.
  • Technical credibility.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.